Metapneumovirus Immunogens and Related Materials and Methods
AssigneesOhio State Innovation Foundation, Research Institute At Nationwide Children's Hospital
InventorsJianrong Li, Yongwei Wei, Yu Zhang, Mark E. Peeples
Life of this patent
Estimating the term…
Abstract
The present invention provides compositions useful to induce immune response to human metapneumovirus. Also provided are related materials and methods, including methods to induce an immune response in a mammal, comprising administering the compositions herein.
Claims71
A composition comprising a nucleic acid molecule encoding a human metapneumovirus (hMPV) having a mutated integrin-binding motif (RGD motif) in a fusion (F) protein of hMPV, wherein the RGD motif is mutated as compared to wildtype hMPV.
A recombinant human metapneumovirus (hMPV) comprising a mutated integrin-binding motif (RGD motif) in a fusion (F) protein of hMPV capable of inducing neutralizing antibody and a T cell immune response in a mammal without inducing clinical symptoms of hMPV infection, wherein the RGD motif is mutated as compared to wild-type hMPV.
A vaccine against human metapneumovirus (hMPV) infection comprising a recombinant hMPV, wherein the recombinant hMPV comprises a mutated integrin-binding motif (RGD motif) in a fusion (F) protein of hMPV.
An immunogenic composition comprising an attenuated, avirulent human metapneumovirus (hMPV) strain, wherein the attenuated, avirulent hMPV strain is selected from the group consisting of:
- the attenuated hMPV rhMPV-R329K deposited with the American Type Culture Collection (ATCC);
- and the attenuated hMPV rhMPV-D331A deposited with the ATCC.
A method for inducing a protective immune response again human metapneumovirus (hMPV) in a mammal comprising administering to the mammal a pharmaceutically effective amount of attenuated, avirulent human metapneumovirus (hMPV) strain, wherein the attenuated, avirulent hMPV strain is selected from the group consisting of:
- the attenuated hMPV rhMPV-R329K deposited with the American Type Culture Collection (ATCC);
- and the attenuated hMPV rhMPV-D331A deposited with the ATCC.
A method of producing an immunogenic composition, comprising admixing attenuated, avirulent human metapneumovirus (hMPV) strain, wherein the attenuated hMPV strain is selected from the group consisting of:
- the attenuated hMPV rhMPV-R329K deposited with the American Type Culture Collection (ATCC);
- and the attenuated hMPV rhMPV-D331A deposited with the ATCC, with a pharmaceutically acceptable carrier, vehicle, and/or excipient.
A method of attenuating a human metapneumovirus (hMPV) comprising mutating an integrin-binding motif (RGD motif) in a fusion (F) protein of the hMPV, wherein the RGD motif comprises at least one amino acid mutation selected from the group consisting of:
- alanine substitution compared to wildtype;
- substitution of at least one amino acid having the same charge compared to wildtype;
- substitution of at least one amino acid having the opposite charge as wildtype;
- and mutation resulting in an avian metapneumovirus (aMPV) F protein mimic, wherein the RGD motif is mutated as compared to wild-type hMPV, and wherein mutation of the RGD mutation results in attenuation of the hMPV.
Dependencies are inferred from the claim text.